Guardant Health, Inc.·4

Mar 18, 5:40 PM ET

Hidalgo Medina Manuel 4

Research Summary

AI-generated summary

Updated

Guardant Health Director Hidalgo Medina Receives 232 Shares

What Happened

  • Manuel Hidalgo Medina, a director of Guardant Health (GH), had 232 restricted stock units (derivative awards) convert into 232 common shares on 2026-03-17. The reported price is $0.00 per share, so no cash was paid or received in the conversion.
  • The Form 4 shows two matching entries: 232 shares "acquired" (underlying shares issued) and 232 shares "disposed" of as a derivative — this reflects the conversion/settlement of the RSUs into common stock, not a market sale.

Key Details

  • Transaction date: 2026-03-17; Form 4 filed: 2026-03-18 (timely filing).
  • Reported price: $0.00 per share; total cash value reported: $0.
  • Shares owned after transaction: not specified in the provided excerpt of the filing.
  • Footnotes: F1 notes the RSU grant (dated July 17, 2024) vests over four years (25% at one year, then monthly over three years). F2: not applicable for RSUs.
  • Transaction type: conversion/settlement of restricted stock units (derivative conversion), coded as M on the Form 4.

Context

  • This is a routine equity compensation vesting event (RSUs converting to common shares), not an open‑market purchase or sale. Such conversions are part of standard executive/director compensation and do not by themselves indicate a buy or sell signal.
  • The filing shows no immediate sale of the underlying shares; if the insider later sells, that would be reported in a separate transaction.